Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Rozenbaum

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
Climacteric : the Journal of the International Menopause Society|November 7, 2002
Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal womenH Rozenbaum, O Chevallier, M Moyal, et al.
Clinical Therapeutics|October 27, 2010
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluationsStefan Vegter, Mark H Rozenbaum, Roelien Postema, et al.
The American Journal of Gastroenterology|April 1, 1987
Immune basis for cimetidine-induced pancytopeniaA Nagler, H Rozenbaum, R Enat, et al.
Epidemiology and Infection|November 26, 2011
Modelling the impact of extended vaccination strategies on the epidemiology of pertussisM H Rozenbaum, R De Vries, H H LE, et al.
Expert Review of Vaccines|December 21, 2012
Dynamic models for health economic assessments of pertussis vaccines: what goes around comes aroundMark H Rozenbaum, Elisabetta De Cao, Tjalke A Westra, et al.
Vaccines|November 26, 2024
The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the USAleksandar Ilic, Maria J Tort, Alejandro Cane, et al.
Vaccine|February 26, 2026
A comparative analysis of pediatric pneumococcal vaccination strategies: a dynamic model of PCV20 vs. PCV15 and PCV13Michele Wilson, Benjamin M Althouse, Aaron Lucas, et al.
Clinical Therapeutics|August 24, 2010
Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the NetherlandsMark H Rozenbaum, Eelko Hak, Tjip S van der Werf, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 6, 2022
The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing DataMarcel H Schöttler, Friso B Coerts, Maarten J Postma, et al.
Infectious Diseases and Therapy|January 27, 2023
Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United StatesMark H Rozenbaum, Jen Judy, Diana Tran, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Climacteric : the Journal of the International Menopause Society|November 7, 2002
Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal womenH Rozenbaum, O Chevallier, M Moyal, et al.
Clinical Therapeutics|October 27, 2010
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluationsStefan Vegter, Mark H Rozenbaum, Roelien Postema, et al.
The American Journal of Gastroenterology|April 1, 1987
Immune basis for cimetidine-induced pancytopeniaA Nagler, H Rozenbaum, R Enat, et al.
Epidemiology and Infection|November 26, 2011
Modelling the impact of extended vaccination strategies on the epidemiology of pertussisM H Rozenbaum, R De Vries, H H LE, et al.
Expert Review of Vaccines|December 21, 2012
Dynamic models for health economic assessments of pertussis vaccines: what goes around comes aroundMark H Rozenbaum, Elisabetta De Cao, Tjalke A Westra, et al.
Vaccines|November 26, 2024
The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the USAleksandar Ilic, Maria J Tort, Alejandro Cane, et al.
Vaccine|February 26, 2026
A comparative analysis of pediatric pneumococcal vaccination strategies: a dynamic model of PCV20 vs. PCV15 and PCV13Michele Wilson, Benjamin M Althouse, Aaron Lucas, et al.
Clinical Therapeutics|August 24, 2010
Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the NetherlandsMark H Rozenbaum, Eelko Hak, Tjip S van der Werf, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 6, 2022
The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing DataMarcel H Schöttler, Friso B Coerts, Maarten J Postma, et al.
Infectious Diseases and Therapy|January 27, 2023
Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United StatesMark H Rozenbaum, Jen Judy, Diana Tran, et al.
Pageof 8